Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LTA4H | P09960 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8993951 | 0.98 | SMN1; SMN2 (0.60) | SMN1; SMN2ALOX5CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL8993937 | 0.95 | SMN1; SMN2 (0.63) | SMN1; SMN2ALOX5CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL2405898 | 0.90 | SMN1; SMN2 (0.65) | SMN1; SMN2ALOX5CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL9746067 | 0.85 | DNM1 (0.54) | SMN1; SMN2ALDH1A1LTA4HKMT2ATDP1 | |
| SCHEMBL8993953 | 0.85 | CYP1A2 (0.45) | SMN1; SMN2ALOX5CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL31478350 | 0.84 | LMNA (0.50) | SMN1; SMN2ALDH1A1LTA4HKMT2A | |
| SCHEMBL31478356 | 0.84 | LMNA (0.50) | SMN1; SMN2ALDH1A1LTA4HKMT2A | |
| SCHEMBL31478349 | 0.84 | LMNA (0.50) | SMN1; SMN2ALDH1A1LTA4HKMT2A | |
| SCHEMBL7712007 | 0.84 | KMT2A (0.49) | SMN1; SMN2ALOX5CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL8993978 | 0.84 | CYP1A2 (0.44) | SMN1; SMN2ALOX5CYP4F2CYP4A11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9720004-B2 | Immunoassays employing non-particulate chemiluminescent reagent | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160231336-A1 | IMMUNOASSAYS EMPLOYING NON-PARTICULATE CHEMILUMINESCENT REAGENT | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-9347947-B2 | Immunoassays employing non-particulate chemiluminescent reagent | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9023998-B2 | Near infrared fluorogen and fluorescent activating proteins for in vivo imaging and live-cell biosensing | CARNEGIE MELLON UNIVERSITY (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023998-B2 | Near infrared fluorogen and fluorescent activating proteins for in vivo imaging and live-cell biosensing | CARNEGIE MELLON UNIVERSITY (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023998-B2 | Near infrared fluorogen and fluorescent activating proteins for in vivo imaging and live-cell biosensing | CARNEGIE MELLON UNIVERSITY (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140243509-A1 | NEAR INFRARED FLUOROGEN AND FLUORESCENT ACTIVATING PROTEINS FOR IN VIVO IMAGING AND LIVE-CELL BIOSENSING | CARNEGIE MELLON UNIVERSITY | 2014-08-28 | — | — | US | disclosed |
| US-20140243509-A1 | NEAR INFRARED FLUOROGEN AND FLUORESCENT ACTIVATING PROTEINS FOR IN VIVO IMAGING AND LIVE-CELL BIOSENSING | CARNEGIE MELLON UNIVERSITY | 2014-08-28 | — | — | US | disclosed |
| US-20140243509-A1 | NEAR INFRARED FLUOROGEN AND FLUORESCENT ACTIVATING PROTEINS FOR IN VIVO IMAGING AND LIVE-CELL BIOSENSING | CARNEGIE MELLON UNIVERSITY | 2014-08-28 | — | — | US | disclosed |
| US-20100233725-A1 | IMMUNOASSAYS EMPLOYING NON-PARTICULATE CHEMILUMINESCENT REAGENT | SIEMENS HEALTHCARE DIAGNOSTICS INC., A CORPORATION OF CALIFORNIA (US) | 2010-09-16 | — | — | US | disclosed |
| US-7635571-B2 | photosenstizer generates singlet oxygen which oxidatively cleaves the linker to form a product which can be detected in a sandwich detection assay; kits | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2009-12-22 | — | — | US | disclosed |
| US-7635571-B2 | photosenstizer generates singlet oxygen which oxidatively cleaves the linker to form a product which can be detected in a sandwich detection assay; kits | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2009-12-22 | — | — | US | disclosed |
| US-7229842-B2 | Metal chelate containing compositions for use in chemiluminescent assays | DADE BEHRING MARBURG GMBH (DE) | 2007-06-12 | — | — | US | disclosed |
| US-7229842-B2 | Metal chelate containing compositions for use in chemiluminescent assays | DADE BEHRING MARBURG GMBH (DE) | 2007-06-12 | — | — | US | disclosed |
| US-6406667-B1 | FLUORESCENT COMPOUNDS FOR CHEMILUMINESCENT COMPOUNDS | DADE BEHRING MARBURG GMBH (DE) | 2002-06-18 | — | — | US | disclosed |
| EP-1078265-A1 | CHEMILUMINESCENT COMPOSITIONS FOR USE IN DETECTION OF MULTIPLE ANALYTES | DADE BEHRING INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999042838-A1 | CHEMILUMINESCENT COMPOSITIONS FOR USE IN DETECTION OF MULTIPLE ANALYTES | DADE BEHRING INC. (US) | 1999-08-26 | — | — | WO | disclosed |
| US-5532171-A | PHENOTHIAZINE DYES FOR PHOTODYNAMIC THERAPY OF CANCER OR IMMUNOASSAY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| US-5344928-A | Phenothiazine compounds for cancer treatment or immunoassay using chemiluminescence | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-09-06 | — | — | US | disclosed |
| EP-0510668-A2 | Phenothiazine derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243509-A1 | NEAR INFRARED FLUOROGEN AND FLUORESCENT ACTIVATING PROTEINS FOR IN VIVO IMAGING AND LIVE-CELL BIOSENSING | FUCA1, TYR, HBG2 | SMN1; SMN2 3629/4885ALOX5 2666/4885CYP4F2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.